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Vaccinia virus-infected cells were treated enzymatically 
to remove H-2 antigenic' sites. The effect 01 this procedure 
on virus-specific cell-mediated cytolysis (CMC) and virus-
specific antibody-mediated cytolysis (AMC) was tested. Due 
to the inhibition of cellular proteinsynthesis by the va,," 
cinia virus infection, H-2 antigenie sites were not resynthe-
sized while there was a continuous production 01 viral 
surface antigens. 
These cells with a high concentration 01 viral surface 
antigens and decreased H-2 determinants could be used as 
targets in the virus specific AMC. But they were not lysed 
in the virus specific CMC which emphasizes the signifi-
cance 01 H-2 antigens during recognition 01 virus-specific 
determinants by T cells. 
The action of cytotoxic lym phocytes (CL) S against target 
cells infected with certain viruses, such as lymphocytic chorio-
meningitis (LCM) virus, ectromelia virus or vaccinia virus, is 
H-2 antigen restricted (1-3). Specific lysis occurs only if 
attacker and target cells share serologically defined (SD ) 
antigens of the major histocompatibility complex (MHC). In 
the vaccinia virus system, cell-mediated lysis can be inhibited 
by H-2 alloantisera binding to SD specificities ofthe target cell 
(4). Other experiments indicate that a virus infection causes a 
reduction of normal H-2 antigenic sites, probably by modifying 
them (2, 5). Such a virus-induced alteration was suggested 
earlier by Zinkernagel and Doherty in the LCM virus system 
(6). All these data indicate that a modified H-2 antigen, 
associated to the K or D end of the MHC, seems to be the 
target for virus-specific sensitized T cells. The same conclusion 
was drawn by Shearer et al., who found a similar H-2 
dependency of the T cell response by using trinitrophenyl 
(TNP) as modifying agent (7, 8). 
In contrast to these results, Dennert reported lysis of 
TNP-modified syngeneic target cells by T cells sensitized 
against allogenic TNP-modified cells. His explanation was 
that CL not only act against the modified H-2, but also against 
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the hapten (9). The blocking effect of viral antibodies on 
cell-mediated cytolysis (CMC) could be interpreted in the 
same way (3, 10). 
Considering these conflicting results, we tested whether 
syngeneic H-2 is necessary for T cell action or if the agent 
modifying the cell surface, such as the viral surface antigen, 
suffices as a target for T cell-mediated lysis. Removal of H-2 
antigenic sites from the target cell decreases cytolysis hy 
allogeneic-sensitized CL (11). This inhibition is fully reversible 
after resynthesis of the H-2 antigens. Removal of neuraminic 
acid from the target cell surface increases CMC (12) and 
antibody-mediated cytolysis (AMC) without influencing H-2 
alloantibody-absorbing capacity (13). In our experiments in-
fected cells were treated with different enzymes in order to 
obtain target cells with decreased H-2 antigenic sites but 
without alterations of the concentration of viral surface anti-
gens. 
MATERIAL AND METHODS 
Animals 
C3HtrIF inbred mice, haplotype H-21< (purchased from G. 
L. BornholdgArd, Ry, Denmark) aged between 6 and 10 weeks 
were used. 
Virus 
Vaccinia virus, strain WR, propagated on VERO cells 
(monkey kidney cells) was diluted to about 10· TCID50/ml in 
Eagle's minimal essential medium (MEM, Behringwerke, Mar-
burg/Lahn, W. Germany) supplemented with 100 Jlg/ml strep-
tomycin and 100 IU /ml penicillin (1 % SP). 
Antisera 
Anti-vaccinia serum. Anti-vaccinia serum was raised in 
rabbits by 3-fold challenge with 5 ml vaccinia virus given 
intramuscularly at 2-week intervals after intracutaneous sensi-
tization. The animals were bled 1 week after the last injection. 
Sera were inactivated and stored at -70°C. The cytotoxic titer 
of the sera measured in a HCr-release assay, using infected 
L-929 cells as targets and guinea pig serum as complement 
source, was about 1024 to 2048. An anticomplementary activity 
of the sera was demonstrable to a dilution of about 1/8. 
Anti-H-2 serum. Anti-H-2 serum was obtained from D. J. G. 
Ray, Transplantation and Immunology Branch, NIAID, 
National Institutes of Health, Bethesda, Maryland. We used 
charge 3b, raised in recipient-donor strains (C3H-H-2° x 129) 
anti-C3H, genotypes (H_~1l< x H_2b ) anti-H-2k • The serum is 
mainly directed against specificities coded by H-2 K genes 
(14). No cross-reactivity with other private H-2 specificities 
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could he observed by immunofluorescence or complement-
dependent antibody-mediated cytolysis. 
Target cells 
L-929 cells (haplotype H-2k ), obtained from Dr. Lehmann-
Grube, Hamburg, were cultivated in Eagle's MEM supple-
mented with 10% inactivated calf serum and 1% SP. 
Infection of target cells. About 5 x 108 to 1 X 107 L-929 cells 
growing as monolayer cells in glass bottles were washed with 
fresh serum-free medium and then incubated with 10 to 15 ml 
vaccinia virus suspension on a rocker-platform at 37°C. After 2 
hr the virus dilution was discarded and fresh serum-free 
medium was added. The cells were used for tests 18 to 24 hr 
later. 
Enzymatic treatment. 
The following enzymes were used: 1) trypsin .from bovine 
pancreas, crystallized, lyophilized, 2 units/mg (Merck, Darm-
stadt, W. Germany, lot 24579); 2) pronase E lyophilized, 70 
PVK/mg (Merck, lot 2433); 3) papain, water soluble 3.5 M 
Anson V/mg (Merck, lot 7144); 4) neuraminidase from Vibrio 
comma (VCN), 500 neuraminidase units/ml (Behringwerke, 
Marburg/Lahn, W. Germany). The enzymes were dissolved 
and diluted in serum-free MEM. Vsed enzyme concentrations 
may be seen in Table I. 
Cells prepared for enzymatic treatment were washed twice 
with serum-free medium and diluted to a concentration of 2.5 
x 108 cells/mI. The enzymatic treatment was performed at 
37°C with intermittent shaking at pH 6.5 to 7.0 for 20 min 
(proteolytic enzymes) or 30 min (VCN). Treatment with 
papain was carried out in the presence of 0.01 M cystein 
(L( +) Cysteine chloride, Merck, lot 2839). After enzymatic 
treatment the cells were washed three times with MEM 
supplemented with 20% fetal calf serum (FCS). 
Cells were counted and viability was determined by the 
trypan blue exclusion test. Vnder the enzyme concentrations 
used viability did not fall below 70 to 80%. The cells were 
TABLE I 
Schedule o{ enzymatic treatment· 
Enzyme Trypsin Pronase Papain VCN Concentration 
I'g/ml I'g/ml I'g/ml units/ml 
1 0.5 0.5 5 5 
2 1 10 20 
3 2 2 20 50 
4 5 5 50 100 
5 10 10 100 200 
6 20 20 200 
a Enzymatic treatment: 2.5 x 10· overnight vaccinia virus-infected 
L-929 cells suspended in 1 ml MEM were incubated with different 
concentrations of enzymes at pH 6.5 to 7 for 15 to 20 min (proteolytic 
enzymes) or 30 min (VCN) at 37°C humidified atmosphere with 8% 
CO •. Enzymatic action was stopped by addition of 2 ml FCS and 3-fold 
washing. Viability was tested with trypan blue; under the enzyme 
concentrations used viability did not fall below 80%. The cells were 
stored in Eagle's supplemented medium + 20% FCS at 37°C and 
labeled for 1 hr with "Cr before use. Controls were: enzymatically 
treated noninfected L-929 cells, untreated infected and noninfected 
cells, and cells treated with enzymes in the presence of Trasylol, a 
proteinase inhibitor (Trasylol, 5000 units, Bayer Leverkusen). 
Enzymatically treated cells were used as targets 4 hr later in 
virus-specific tests. 
stored in Eagle's MEM supplemented with 20% FCS before 
use. For virus-specific cytotoxic assays, carried out 4 hr after 
enzymatic treatment, cells were labeled 1 hr before with about 
100 ßlCi HCr (sodium chromium; Amersham, Buchler, 
Braunschweig No. CJS1P, specific activity 100 to 200 mCi/mg 
Cr) per 5 x 108 cells. For allogenic CMC, cells were labeled 
before enzymatic treatment and used as targets immediately 
after treatment. 
Immunofluorescence 
5 x 10& infected or normal L-929 cells were incubated for 30 
min 4°C with 0.1 ml anti-vaccinia serum from rabbit or 
anti-H-2 serum diluted 1/5 with medium. Cells were then 
washed three times with phosphate-buffered saline (PBS) and 
incubated for another 30 min with a fluorescein-isothiocya-
nate-conjugated anti-rabbit 'Y.globulin from goat or anti-
mouse 'Y-globulin from rabbit (Behringwerke, Marburg/Lahn, 
W. Germany), at room temperature or at 4°C. 
Antibody-mediated lysis 
Vaccinia-specific AMC. 5 x 10· L-929 cells infected 24 hr 
previously were labeled 1 hr before with HCr and then 
incubated in a volume of 0.05 ml in medium with 0.05 ml 
anti-vaccinia serum 1/10 diluted in microplates for 30 min at 
37°C. Then 0.1 ml guinea pig complement was added. After 4 
hr incubation at 37°C the cellfree supernatant and the cell 
pellet were separately removed, the radioactivity was deter-
mined and the percentage of Cr-release was calculated by using 
the formula: 
% Cr-release = 
Radioactivity in the supernatant 
Background radioactivity x 100 
Total radioactivity (supernatant 
+ pellet) 
For each value the mean of 4 to 5 wells was used. Controls 
included spontaneous 6lCr-release, &lCr-release in the presence 
of complement alone, antibody alone, normal rabbit serum, 
and normal rabbit serum together with complement. The 
activity of the antiserum on normal L-929 cells was determined 
as weIl. 
The percentage of vaccinia-specific AMC was calculated by 
using the formula: 
( 
% Cr-release target ) _ ( % Cr-release target ) 
cells + antibody + C cells + antibody + 5% 
% Spec.AMC 
Absorption of H-2 alloantisera. Five-tenths milliliter of 
anti-H-2k serum in Eagle's MEM diluted 1/2 was absorbed on 
5 x 107 infected enzymatically treated or untreated L-929 cells 
for 30 min at 37°C. Cells were pelleted by centrifugation 10 min 
at 3000 rpm, and the cellfree supernatant was carefully re-
moved. The titer of the absorbed serum (supernatant) was de-
termined in a 51Cr-assay: 5 x 10· 51Cr-Iabeled spleen lympho-
cytes from C3H mice (haplotype H-2k ) were filled in a volume 
of 0.05 per weH in microplates with 0.05 ml of absorbed and un-
absorbed serum diluted in log 2 steps with MEM. After 30 min 
0.1 ml of complement was added. After 4 hr incubation at 37°C 
the percentage of Cr-release was recorded. Lysis was calcu-
lated as descrihed in the previous paragraph. The cytotoxic 
activity of the H-2k serum reached a plateau of activity between 
the dilution of 1/16 and 1/64. The mean value of 44.8% cytotoxi-
city was taken as 100% serum activity. 
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Cell-mediated cytolysis 
Vaccinia virus-specific CMC. The activity of spleen lympho-
cytes of C3H mice infected 6 days previously with 108 TCID,o 
vaccinia virus was tested in an 18-hr Cr-release assay as 
described earlier (3). Target cells were infected L-929 cells, 
untreated or treated with different amounts of enzymes. 
Briefly,5 x 108 spleen lymphocytes from immunized or normal 
C3H mice were incubated in microplates with 5 x 10· normal 
or vaccinia virus-infected, enzymatically treated or untreated 
"Cr-Iabeled L-929 cells in a volume of 0.2 ml at 37°C in a 
humidified atmosphere with 7% CO 2 • Eighteen hours later 
supernatant and cell pellet were separately removed and 
Cr-release was calculated. Controls included spontaneous 
Cr-release (20 to 25% untreated cells, 25 to 35% enzymatically 
treated cells) and the Cr-release of normal cells in the presence 
of immune or normal lymphocytes. 
The percentage of specific lysis was calculated as folIows: 
Spec. lysis = % Cr-release by sensitized lymphocytes 
- % Cr-release by normal lymphocytes 
For each value four to five weHs were used. Data were subjected 
to statistical analysis with determination of the mean and the 
standard error of the mean (S.E.M.) and calculated for 
significance by the Student t-test. 
In vitro response against alloantigens. The assay was per-
formed according to the method of Wagner (15). In brief, 1 x 
108 mitomycin C-treated C3H spleen cells (stimulator cells) 
were incubated with 4 x 108 DBA/2 spleen cells (responder 
cells) in 2 ml Dulbecco's modified medium (GIBCO) supple-
mented with 2 x 10- 6 M mercaptoethanol 10% FCS and 100 
/lg/ml penicillin and streptomycin. Five or six days later the 
cells were harvested and their activity on 5lCr-Iabeled L-929 
celIs (untreated or treated immediately before with different 
concentrations of papain) was tested in a 6- to 10-hr assay by 
using a ratio of 50: 1 attacker cells to target cel!. The percent-
age of specific cytolysis was calculated by using the same 
formula as in the virus specific CMC. 
RESULTS 
Alteration of surface antigens after enzymatic treatment of 
target cells. The effect of enzyme treatment on surface antigens 
of virus-infected L-929 cells was controlled by indirect immu-
nofluorescence (IF). Virus-specific and H-2-specific IF were 
found reduced or even abolished directly after treatment of 
cells with proteolytie enzymes. VCN treatment had no effect. 
Repetition of virus specifie IF 4 hr and 24 hr later indicated 
that viral surface antigens had been resynthesized; immuno-
fluoreseenee was even intensified on treated eeHs. H-2-speeifie 
IF studies showed that H-2 antigenie sites remained redueed 
under the experimental eonditions. 
Vaccinia specific antibody-mediated cytolysis of enzymati-
cally treated cells. To verify the impression given by the 
immunofluoreseence, the activity of an anti-vaccinia serum 
was tested on vaecinia virus-infected eells treated 4 hr previ-
ously with different concentrations of papain, trypsin, pronase, 
or VCN. Untreated and enzymatieally treated infected and 
uninfected L-929 cells were labeled for 1 hr with HCr and then 
used as targets for AMC. The anti-vaccinia serum showing an 
anti-eomplementary activity to a dilution of 1/8 was diluted 
1/10 with Eagle's MEM. Guinea pig serum was used as comple-
ment source. Speeifie release of "Cr did not oeeur in the pres-
enee of normal rabbit serum or when uninfected L-929 cells 
were used as targets. 
As shown in Table H, significant speeifie lysis of vaccinia 
virus-infected L-929 eells was observed after enzymatic treat-
ment of vaceinia virus-infected L-929 cells. 
Lysis was even inereased after treatment with high doses of 
enzymes, especially in the ease of VCN treatment. This 
demonstrates that viral surface antigens neeessary for comple-
ment dependent lysis by viral antibodies were resynthesized 4 
hr after proteolytic treatment. The increase of specifie lysis 
may be due to an unmasking of antibody or eomplement-bind-
ing sites, to a removal of sterie hindrances, or to a change of the 
surface charge. An enhanced resynthesis of viral surfaee 
antigens may be possible as weIl. 
Reduction of H-2 antigenic sites by enzymatic treatment of 
target cells. To demonstrate resynthesis of viral surface anti-
gens, antibody-mediated eytolysis was suffieient. Absorption 
studies were performed since AMC does not estimate eoneen-
tration differences ofH-2 antigens on cell surfaces exactly (16). 
Equal amounts of infected L-929 eells and infeeted cells 
treated with the highest and lowest enzyme eoneentrations 
were incubated with an H_2k serum at 37°C for 30 min. The 
absorbed sera were titrated for the amount of residual antibody 
activity on 6lCr-labeled C3H lymphoeytes and eompared with 
the activity of the nonabsorbed serum (Fig. 1). 
Treatment of cells with neuraminidase did not alter the 
eapability of eeHs to absorb the antibody. Almost the same 
reduction of activity after absorption on treated and untreated 
ceHs could be observed. This indieates that antibody-binding 
sites eannot be removed by neuraminidase_ As shown first by 
Nathenson and Davies (17), the chemieal structure of H-2 
mouse isoantigens seems to be glyeoproteins wh ich eontain 
sialic acid. But the neuraminidase-sensitive siaHc acid in the 
H-2 antigens probably is not involved in the antigenic determi-
nants, sinee neuraminidase treatment does not affeet their 
aetivity. 
Treatment of cells with proteolytie enzymes eauses a redue-
tion of the absorption capacity of the eelIs. Papain used to 
disolve H-2 or HL-A antigens for ehemical analysis (18) was 
most effective. No significant amount of alloantibody eould be 
absorbed by eells treated with a high eoncentration of papain 
which is refleeted by nearly identical slopes of eytolytic activity 
TABLE II 
Enzyme Vaccinia Specific AMC· of Infected Enzyrnatic 
Concen- Treated L-929 Cells 
tration Trypsin Pronase Papain VCN 
18.8 ± 2.0 26.6 ± 1.6 24.6 ± 0.2 13.9 ± 2.4 
2 20.2 ± 0.8 27.8 ± 0.4 33.7 ± 1.4 9.3 ± 2.3 
3 13.6 ± 3.0 32.9 ± 1.0 24.4 ± 1.8 14.2 ± 2.4 
4 16.6 ± 1.9 28.5 ± 1.6 23.4 ± 0.6 15.6 ± 3.6 
5 18.6 ± 1.6 28.3 ± 1.2 29.1 ± 2.5 66.8 ± 2.4 
ControlC 13.6 ± 1.8 8.8 ± 1.3 
a See Table I. 
• Vaccinia-specific AMC was performed 4 hr after enzymatic treat-
ment of infected L-929 cells in a 4-hr "Cr-release assay, using 
overnight infected L-929 cells as targets, guinea pig serum as comple-
ment source, and antibody from rabbits after vaccinia virus infection. 
Spontaneous "Cr-release of enzymatically treated cells: 20 to 25%. 
C Control: vaccinia-specific AMC of infected L-929 cells without 
enzymatic treatment in two different assays for proteolytic enzymes 
and VCN. Each value represents mean of n = 4 weHs ± S.E.M. 
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Figure 1. Reduction of H-2 antigenic sites by enzymatic treatment of target cells. The residual cytotoxic activity of an anti H-2k serum was 
tested on C3H spleen lymphocytes after absorption on infected enzymatically treated and untreated L-929 cells. Cytotoxic activity of the 
unabsorbed serum control (O~), after absorption on infected L-929 cells (e---e), after absorption on infected L-929 cells treated with the 
lowest (.--.) and highest (0--0) enzyme concentration (see Table 1). The plateau activity of the serum (44.8% ± 3.2%) was taken as 
100% serum activity. Data represent the mean of at least four wells ± S.E.M. 
shown by control and absorbed serum. Pronase and trypsin in 
concentrations tolerable for the cells caused a weaker but 
significant decrease of the ability of the cells to absorb an H-2 
antibody. 
Alteration o[ cell-mediated cytolysis by enzymatic treatment 
o[ target cells 
Virus speci[ic CMC. The cytotoxic activity of virus-specific 
sensitized lymphocytes was tested on normal and infected L-
929 cells treated 4 hr previously with different enzymes. Im-
mune T cells can only lyse syngeneic infected target cells. 
AHogenic infected or syngeneic noninfected ceHs are not killed. 
We got the same results after enzymatic treatment of target 
ceHs; neither syngeneic noninfected nor allogenic infected 
control cells were lysable after enzymatic treatment. Enzy-
matic treatment had influence only on the lysis of syngeneic 
infected ceHs. 
Removal of sialic acid resulted in enhanced CMC. Treat-
ment of target ceHs with proteolytic enzymes diminished the 
lysis of target ceHs by the effector ceHs. Papain treatment was 
most effective (Fig. 2). 
Response against alloantigens. To prove the efficiency of 
enzymatic treatment on H-2 antigens, L-929 cells treated with 
papain were used as targets for allogenic CL sensitized against 
H-2k • Untreated L-929 target ceHs were used as controls. 
Treatment of target cells with different concentrations of 
papain resulted in the decrease of cytolysis by allogenic killer 
ceHs. As uninfected L-929 ceHs are less fragile than infected 
L-929 ceHs, we could use higher concentrations of papain in 
comparison to virus-specific CMC (Fig. 3). 
The enhanced sensitivity of virus-specific CM C to enzymatic 
treatment suggests an influence of viral infection on H-2 
concentration (5) due to blocking ofresynthesis and possibly to 
increased susceptibility of cell membranes for proteolytic 
treatment. After prolongation of the incubation per iod of 
allogenic CMC to 10 hr, no killer ceH inhibition was seen, 
which reflects resynthesis of H-2 antigens during this test 
period. To compare the resynthesis of target antigens for CMC 
that means probably H-2 antigens on uninfected and vaccinion 
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Figure 2. Alteration of cell-mediated lysis after enzymatic treat-
ment of target cells. The action of spleen lymphocytes of C3H (H_2k ) 
mice sensitized against vaccinia virus and normal control mice was 
tested on infected L-929 (H_2k ) cells. The figure represents data ± 
S.E.M. from four independent assays. The O-line stands for the lysis 
of untreated infected target cells by virus immune effector cells after 
subtraction of lysis in presence of normallymphocytes (specific lysis). 
The activity of the same effector cells was tested on target cells treated 
with different concentrations (see Table 1) of enzymes. t:.--t:., VCN; 
0----0, 0- - - - -0, pronase; e----e, e- - --e, trypsin; and 
0--0, 0- - - - -0, papain. Some examples of uncorrected values 
are given to explain the experimental schedule and the transcription 
of the data into the figure. Control lysis of untreated target cells by 
NL (normal lymphocytes) 20.3 ± 3.2, IL (immune lymphocytes) 64.3 
± 2.1, 0--0 papain concentration 1: NL 23.1 ± 2.4, IL 57.0 ± 1.2, 
papain concentration; 3: NL 21.4 ± 1.3, IL 47.4 ± 3.8, papain concen-
tration; 5: NL 25.4 ± 0.5, IL 40.7 ± 2.8. 0----0, pronase concentra-
tion; 3: NL 28.6 ± 3.4, IL 60.0 ± 2.1. e----e, trypsin concentration; 
3: NL 26.1 ± 2.8, IL 53.3 ± 1.4. 
Alteration of specific lysis was calculated using the formula: 
% alteration specific lysis enz. treated cells 
spec. lysis of untreated cells 
1 x 100. 
Differences between lysis of control and enzymatically treated target 
cells are statistically significant, p-values: Papain concentration. 1: p 
<0.1; 3: p < 0.001; 5: p < 0.001; prQnase 3: p <0.1; trypsin 3: p < 
0.01 
infected target cells, the activity of anti-H-2k and anti-viral 
CL was tested in a 6- and 16-hr assay on uninfected and in-
fected L-929 target cells pretreated with papain. Untreated 
target cells were used as controls, (Table III). Uninfected tar-
get cells, which were treated with papain, were not lysed in 6-
hr assay but in a 16-hr assay, whereas vaccinia virus infected 
target cells did not regain their ability to be lysed by allogeneic 
virus-sensitized effector cells or by anti-H-2 killer cells. These 
data reflect the inhibition of cellular protein synthesis after 
vaccinia virus infection (19). The serologie (IF) control for 
H-2 antigens supports the results of CMC. 
DISCUSSION 
The effects of VCN, papain, trypsin, and pronase on 
anti-viral AMC and anti-viral CMC were studied. The main 
results from the present work are that treatment of vaccinia 
virus-infected target cells for a short period of time with a low 
concentration of proteolytic enzymes increased AMC and 
decreased CMC whereas treatment with VCN enhanced both. 
Transplantation antigens are re-expressed within 6 hr after 
rem oval by proteases on noninfected cells. However, 75% ofthe 
antigens are resynthesized 4 hr after enzymatic treatment. 
Since we used cells infected with vaccinia virus, which inhibits 
cellular proteinsynthesis (19), no re-expression of cellular 
surface antigens seemed to take place, which we could show by 
immunofluorescence, absorption studies, and target ceH lysis 
by anti-alloantigen CTL (cytotoxic T lymphocytes). 
The alteration of CMC should be due to the action of 
enzymes on the target cells. An effect of adherent enzymes on 
the effector ceHs seems unlikely. Target cells were used 4 hr 
after enzymatic treatment and, furthermore, CMC should be 
enhanced after gentle enzymatic treatment of effector cells as 
was shown by Kedar et al. (20). The fact that the inhibitory 
activity was reversible in the allogenic control lysis when the 
incubation period was extended to 10 hr argues against 
unspecific inhibitory activities of possibly remaining active 
enzyme concentrations in the test on the effector cells. Treat-
ment of control target cells with more than lO-fold higher 
enzyme coneentrations than in anti-viral CMC had no inhibi-
tory activity on effector cells provided the incubation period 
was sufficient for re-expression of H-2 antigenie determinants. 
Vaccinia surface surface antigens, which are resynthetized 
after a short time (21), suffice for antibody-mediated cytolysis. 
The enhancing effect of enzymatic treatment on AMC may be 
due to inereased sensitivity to lysis by antibody and eomple-
ment or, especially in the case of VCN, to an unmasking of 
antibody-binding sites (22). From the data showing an inhibi-
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Figure 3. Influence of papain treatment oE target cells on cell-
mediated lysis by allogenic killer cells. The activity of anti H-2k killer 
cells was tested on untreated L-929 cells or cells treated with papain. 
The data represent the mean of at least three weHs ± S.E.M_ 0----0, 
CMC tested in a 6-hr assay (specific lysis of control: 56.4%, spontane-
ous "Cr-release: 12.5-18.3%); e----e, CMC tested in a lO-hr assay 
(specific lysis of control: 63.6%, spontaneous "Cr-release: 
17.5-23.9%). Ratio killer cells to target cells 20:1. 
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TABLE III 
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In{luence o{ papain treatment o{ target cells on CMC by killer cells sensitized against alloantigens or vaccinia virusa • • 
Target Cells 
Effector Cells IF (H·2.Antigen)d L·929WR L·929WR· L·929 infected L·929 papain infected papain 
After treatment + + 
% Cr-release 
6-hr assay 
Normal DBA/2 18.7 ± 0.8 19.5 ± 1.3 21.3 ± 2.1 22.0 ± 1.3 
NormalC3H 19.2 ± 2.1 17.3 ± 3.4 23.4 ± 1.2 22.8 ± 1.8 
Anti H_2k DBA/2 46.3 ± 1.4 35.5 ± 1.8 29.4 ± 4.2c 23.1 ± 3.2c 
Anti-vaccinia WR C3H 21.3 ± 0.8 63.4 ± 2.3 22.1 ± 0.7 26.2 ± 2.8c 
After6hr + + (+) 
16-hr assay 
Normal DBA/2 23.5 ± 2.0 22.8 ± 1.2 26.4 ± 2.5 24.7 ± 1.3 
NormalC3H 24.5 ± 1.5 23.4 ± 0.6 27.3 ± 3.1 25.9 ± 1.7 
Anti H·2k DBA/2 58.2 ± 2.1 49.3 ± 4.1 61.4 ± 1.6 30.8 ± 1.4C 
Anti·vaccinia WR C3H 22.4 ± 2.3 82.4 ± 1.9 28.1 ± 2.2 36.2 ± 3.3< 
After 16 hr + + + 
a The activity of anti-H-2k (DBA/2) killer cells (sensitized in vitro) and anti-WR (C3R) killer ceHs (sensitized in vivo) was tested in a 6-hr and 
16-hr assay on untreated normal and infected L-929 target ceHs and ceHs treated with papain (2 mg/mI normal ceHs and 0.5 mg/mi infected ceHs). 
• H-2 specific immunofluorescence was performed immediately after treatment, 6 hr and 16 hr later. 
< Differences of specific lysis between papain-treated and nontreated target cells are statistically significant: p < 0.001. 
d +, Positive IF; ", negative IF; (+) weakly positive IF. 
tion of CMC by antibodies to vaccinia virus-induced antigens 
on the cell surface (3), one would have expected T cell-medi-
ated lysis of cells lacking H-2 antigenic sites. However, as the 
only target on the ceH surface, virus-specific antigens do not 
seem to be sufficient for anti-viral CMC. Similar results were 
presented by R. M. Zinkernagel with the use of virus-infected 
F9 mouse teratoma ceHs as targets (41. Cold Spring Harbor 
Symposium, 1976). Inhibition of CMC by antibody to vaccinia 
virus is possibly due to steric hindrance. 
These results do not support the data wh ich indicate that the 
presence of haptens on ceH surfaces alone can lead to T 
ceH-mediated cytolysis (9). Cytolytic T ceHs directed to new 
antigens on ceHs need, in addition, H-2 antigenic sites on the 
target ceH for their effector function. Reduction of these H-2 
targets by destruction with proteolytic enzymes or by covering 
with H-2 alloantisera decreases the possibility ofvirus-infected 
target ceHs to be lysed by anti-viral CL. This corresponds to 
observations of in vitro lysis of aHogenic target ceHs when a 
reduction of CMC can be observed after proteolytic treatment 
of target cells (11). Removal of sialic acid from the target cells 
enhances their susceptibility to CMC (13). It therefore follows 
that the CL directed against syngeneic virus-modified target 
ceHs acts in an analogous way to the CL directed to alloanti-
gens when the degree of CMC is correlated with the concentra-
tion of K or D region gene products on the target cell (16), 
known to be the main target for aHogenic CMC (23). 
Viewing the different activities of cytolytic T ceHs on 
aHogenic ceHs or syngeneic (probably H-2 altered) ceHs, which 
are virus infected, chemicaHy treated, or express H-Y specific 
gene products (24), it is tempting to assume that the MHC 
performs a sort of "major rejection complex" (Ceppellini, 
personal communication). Cytolytic T ceHs recognize antigenic 
determinants on ceHs, and one could speculate that recognition 
and lysis is possible only via interaction with antigenic 
expressions ofthe K or D region ofthe major histocompatibility 
complex. T ceHs interact with various allogenic or modified 
products of the MHC. New antigenic determinants on ceH 
surfaces which do not interact with K or D structures, should 
not be targets for cytolytic T cells. 
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